Trials of IL-6 inhibition are being conducted in patients with depressive disorder using anti-IL-6 Ab sirukumab phase II (NCT02473289) and anti-IL-6R Ab TCZ phase II (NCT02660528). Here, IL6 is linked to depressive disorder.